Harpoon Therapeutics

Amgen, Inc. ’s Imdelltra (tarlatamab) for extensive-stage small cell lung cancer (ES-SCLC) is one of only two bispecific T-cell engagers (BiTEs) approved in the US to treat solid tumors. As additional

Syndax Pharmaceuticals’ Revumenib PDUFA for NDA – First Review 26 September A new opportunity is opening up in a rare subset of patients with acute leukemia – those with KMT2A rearrangements. Synda

Merck & Co., Inc. gained the delta-like ligand 3 (DLL3)-targeting T-cell engager MK-6070 earlier this year through the $680m acquisition of Harpoon Therapeutics , and now the company is tapping Dai

The Biotech Patient In one of David Poyer’s novels on the career of a fictional US naval officer, a regional war erupts and politicians consult with academics on how such conflicts are resolved. While